Posters
Hydrus microstent reduces intraocular pressure in patients with open-angle glaucoma in combination with cataract surgery: 36 month results from the SPECTRUM global hydrus registry
Poster Details
First Author: A. Fea ITALY
Co Author(s): J. Garcia-Feijo S. Gandolfi M. Nardi M. Rekas P. de Waard
Abstract Details
Purpose:
To assess intraocular pressure (IOP) and hypotensive medication changes after implantation of a dilating Schlemm’s canal scaffold (Hydrus Microstent) in a real-world, heterogeneous glaucoma cohort through a follow-up period of 36 months.
Setting:
Multi-center, open-label post-market registry, with patients from 7 European centers in Italy, Spain, Netherlands, and Poland.
Methods:
Patients with age-related cataracts and open-angle glaucoma were implanted with the Hydrus Microstent, and were followed for 36 months postoperatively. Patients ranged from mild-moderate to refractory glaucoma. Patients were followed under current standard of care. Prior to surgery, data was collected on pertinent medical and ocular history, glaucoma diagnosis, IOP, medication use, best-corrected visual acuity, visual field, and cup-to-disc ratio. Postoperatively, data was collected on IOP, medication use, and adverse events.
Results:
Fifty-five patients underwent combined phacoemulsification and Hydrus Microstent implantation. Preoperatively, mean IOP was 21.8 ± 8.7mmHg, with mean medications of 1.91 ± 1.0. Postoperatively, IOP decreased to 16.4 ± 2.7 mmHg on 0.47 ± 0.9 mean medications at 12 months, and to 16.0 ± 2.9 mmHg on 0.78 ± 1.0 mean medications at 36 months. At 36 months, 76.4% of patients had an IOP less than or equal to 18mmHg and 52.7% of patients were medication free.
Conclusions:
Implantation of the Hydrus Microstent in combination with cataract surgery lowers IOP in patients with open-angle glaucoma in a real-world setting, and offers a continuous, durable alternative to medical therapy for IOP reduction in a wide range of glaucoma severity.
Financial Disclosure:
NONE
